Navigation Links
The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
Date:6/18/2008

WHITE PLAINS, N.Y., June 18 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen jointly announced an agreement today to collaborate on a new Phase I clinical trial. The trial will use Memgen's ISF35, an active immunotherapy approach for treating chronic lymphocytic leukemia (CLL).

Based on its alliance with LLS, Memgen plans to begin a Phase I clinical trial this year for up to 12 patients who have 17p-, refractory or resistant CLL with limited therapeutic options. Patients will receive three infusions of ISF35, followed by up to three courses of FCR (fludarabine, cyclophosphamide and rituximab). After treatment, the patients will be followed for at least one year to determine the safety and efficacy of the regimen.

Charles Prussak, Ph.D., Pharm.D., one of the founders of Memgen, said, "Memgen is very pleased to be working with The Leukemia & Lymphoma Society. ISF35 has the potential to become a cornerstone in treatments for leukemia and perhaps for lymphoma. In the initial Phase I CLL clinical trial of ISF35, conducted by William Wierda, M.D., Ph.D., at The University of Texas M. D. Anderson Cancer Center, a single infusion of ISF35 resulted in the rapid decline in circulating and lymph node bound leukemic cells, induced long-term immune based responses against these cells and sensitized them to standard chemotherapies, even in several patients with drug resistant disease."

In commenting on Memgen's upcoming clinical trial, Louis J. DeGennaro, Ph.D., LLS's chief scientific officer, said, "There is a clear unmet medical need for new therapies to treat refractory or relapsed CLL, in particular the 17p- patients. Many of these patients do not respond to current conventional therapy and their treatment options are severely limited. Our goal is to bring new treatment options to these patients more quickly. The partnership with Memgen accelerates the clinical testing of an immunotherapy and brings us closer to that goal."

The agreement marks the first immunotherapy clinical trial funded by LLS's Therapy Acceleration Program, an innovative program designed to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers.

About Memgen, LLC

Memgen is a biotechnology company with offices in Dallas, TX and San Diego, CA. Memgen was founded four years ago to develop non-toxic and targeted active immunotherapies for the treatment of cancers. Its lead product, ISF35, has demonstrated potent anti-leukemic activity as a single agent while being well tolerated. ISF35 generates none of the immunosuppressive activities associated with standard cancer treatments.

ISF35's results are achieved through its ability to bind to a protein found on leukemic B lymphocytes. This activates a natural immune process that causes malignant cells to become more sensitive to subsequent chemotherapy treatments. This targeted and active approach by ISF35 first makes the leukemias and lymphomas more "visible" to the human immune system. Then, ISF35 activates the immune system so that it can seek out and destroy the cancerous cells.

Memgen is now seeking corporate partners to assist in the development of the ISF35 molecule as it enters advanced stage clinical trials. For more information about Memgen, please visit http://www.memgenbio.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. September is Leukemia, Lymphoma and Myeloma Awareness Month
5. The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients
6. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
7. Leukemia Drug Proves Safe and Effective Over the Long Term
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... 29, 2017 , ... Sterling Global Products is pleased to ... biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs manufactured by this ... Texas, operates more than 350 stores throughout Texas and expanding into northern Mexico ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals ... This begins with the popular ClearLungs Extra Strength formula. To ensure that the effectiveness ... in the following ways:, , Removal of the homeopathic element ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
Breaking Medicine News(10 mins):